LEO LUZNIK to Administration, Intravenous
This is a "connection" page, showing publications LEO LUZNIK has written about Administration, Intravenous.
Connection Strength
0.036
-
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clin Cancer Res. 2018 08 01; 24(15):3519-3527.
Score: 0.036